A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer

This study is testing a combination of two drugs — BL-B01D1 (a targeted drug-antibody combination) and a PD-1 immune checkpoint inhibitor — in people with triple-negative breast cancer (a type with no hormone or HER2 receptors) that cannot be surgically removed or has spread. **You may be eligible if...** - You are 18 to 75 years old with triple-negative breast cancer confirmed by biopsy - Your cancer is locally advanced, recurrent, or has spread to other organs and cannot be removed by surgery - You have not had previous systemic treatment for advanced or metastatic disease - You have at least one measurable tumor - Your ECOG score is 0 or 1 - Your expected survival is at least 3 months **You may NOT be eligible if...** - You have received prior chemotherapy for advanced triple-negative disease - You have serious heart, liver, or kidney problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.